GlassScriptPhysician profile
Ashley Halfast
NPI 1922483866
$3,688.28
in general payments reported to CMS, 2019-2025
20 companies · $914 in 2025
The $914 reported for 2025 was more than what 79% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $378 · 2022: $480 · 2023: $1,138 · 2024: $780 · 2025: $914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,731 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,730.86 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $465.71 | 2023-2025 | |
| Ferring Pharmaceuticals INC. | $366.01 | 2023-2025 | Rebyota |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $360.61 | 2021-2025 | Xifaxan |
| Abbvie INC. | $331.67 | 2021-2025 | |
| Csl Behring | $276.84 | 2022-2025 | Kcentra |
| Alexion Pharmaceuticals, INC. | $262.57 | 2022-2025 | Ultomiris, Soliris |
| Janssen Pharmaceuticals, INC | $259.68 | 2021-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $217.54 | 2022-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $199.78 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $189.72 | 2021-2024 | Dificid, Zerbaxa, Recarbrio |
| Astrazeneca Pharmaceuticals LP | $173.13 | 2021-2023 | Lokelma |
| Shionogi INC | $169.49 | 2022-2024 | Fetroja |
| Insmed, INC. | $78.79 | 2023 | Arikayce |
| Vertex Pharmaceuticals Incorporated | $69.74 | 2025 | |
| Astellas Pharma US INC | $69.05 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $62.84 | 2025 | Vowst |
| Vifor Pharma, INC. | $55.78 | 2022-2023 | Veltassa |
| Melinta Therapeutics, LLC | $32.23 | 2025 | Rezzayo |
| Novartis Pharmaceuticals Corporation | $31.86 | 2023 | |
| Paratek Pharmaceuticals, INC. | $15.24 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Halfast listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.